The Detection Performance of 18F-Prostate-Specific Membrane Antigen-1007 PET/CT in Primary Prostate Cancer A Systemic Review and Meta-analysis

被引:13
|
作者
Huang, Ya-Ting [1 ,2 ]
Tseng, Neng-Chuan [3 ,4 ]
Chen, Yen-Kung [5 ,6 ]
Huang, Kuo-How [7 ]
Lin, Hsiu-Ying [7 ,8 ]
Huang, Ya-Yao [1 ,9 ,10 ]
Hwang, Thomas I. S. [11 ,12 ,13 ]
Ou, Yen-Chuan [14 ,15 ]
机构
[1] Primo Biotechnol Co Ltd, Taipei, Taiwan
[2] Camillian St Marys Hosp Luodong, Dept Med Educ & Res, Yilan, Taiwan
[3] Tungs Taichung Metro Harbor Hosp, Div Nucl Med, Taichung, Taiwan
[4] China Med Univ, Dept Publ Hlth, Taichung, Taiwan
[5] Shin Kong Wu Ho Su Mem Hosp, Nucl Med & PET Ctr, Taipei, Taiwan
[6] Fu Jen Catholic Univ, Sch Med, New Taipei, Taiwan
[7] Natl Taiwan Univ Hosp, Dept Urol, Taipei, Taiwan
[8] Natl Taiwan Univ Hosp, Dept Nursing, Taipei, Taiwan
[9] Natl Taiwan Univ, Coll Med, Inst Med Device & Imaging, Taipei, Taiwan
[10] Natl Taiwan Univ, Mol Imaging Ctr, Taipei, Taiwan
[11] Shin Kong Wu Ho Su Mem Hosp, Dept Surg, Div Urol, Taipei, Taiwan
[12] Fu Jen Catholic Univ, Sch Med, Div Urol, New Taipei, Taiwan
[13] Taipei Med Univ, Dept Urol, Taipei, Taiwan
[14] Tungs Taichung Metro Harbor Hosp, Dept Surg, Div Urol, Taichung, Taiwan
[15] Tungs Taichung Metro Harbor Hosp, Dept Res, Taichung, Taiwan
关键词
F-18-PSMA-1007; PET; CT; prostate-specific membrane antigen; prostate cancer; PSMA; BIOPSY; BIODISTRIBUTION; RADIOTRACERS; RISK; F-18; MRI; MEN; PSA;
D O I
10.1097/RLU.0000000000004228
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Multiple tools are now available to determine the requirement for a biopsy to diagnose prostate cancer, and PET/CT with radiolabeled prostate-specific membrane antigen (PSMA)-targeting radiotracers has been recommended for detecting primary prostate cancer. Particularly, the radiotracer F-18-PSMA-1007 was found to be more favorable for primary tumors compared with other PSMA-targeting radiotracers because of its low clearance via the urinary tract and better image resolution. Thus, we performed a systematic review and meta-analysis to more accurately evaluate the detection performance of F-18-PSMA-1007 PET/CT in primary prostate cancer patients. Methods An update on the databases of PubMed/MEDLINE, EMBASE, and Cochrane Library for comprehensive literature search was performed on September 30, 2021. The pooling detection rate was calculated on a per-patient basis. The pooling median of the SUVmax was analyzed from the included studies. Furthermore, the positive predictive value of F-18-PSMA-1007 PET/CT with pathologic lesions was analyzed using the criterion standard. Results Twelve studies (540 patients total) were included in the meta-analysis. The overall pooling detection rate of F-18-PSMA-1007 per patient was 94%, and the pooling median of SUVmax located at the intraprostate tumor was 16 (range, 3.7-77.7). The positive predictive value of F-18-PSMA-1007 per lesion with histopathological validation was 0.90, detecting regional lymph node metastasis was 0.94, and detecting localized prostatic tumors was 0.84. Conclusions In the current meta-analysis, we revealed the excellent performance of F-18-PSMA-1007 to detect localized prostatic tumor lesions and regional lymph node metastasis. Moreover, the uptake of localized tumors in primary prostate cancer was nearly liver uptake and may be considered a suspicious malignancy if it was equal to or greater than the liver uptake.
引用
收藏
页码:755 / 762
页数:8
相关论文
共 50 条
  • [41] 68Ga-Prostate-specific membrane antigen (PSMA) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis
    Matushita, Cristina S.
    Marques da Silva, Ana M.
    Schuck, Phelipi N.
    Bardisserotto, Matteo
    Piant, Diego B.
    Pereira, Jonatas L.
    Cerci, Juliano J.
    Coura-Filho, George B.
    Esteves, Fabio P.
    Amorim, Barbara J.
    Gomes, Gustavo, V
    Brito, Ana Emilia T.
    Bernardo, Wanderley M.
    Mundstock, Eduardo
    Fanti, Stefano
    Macedo, Bruna
    Roman, Diego H.
    Tem-Pass, Cinthia Scatolin
    Hochhegger, Bruno
    INTERNATIONAL BRAZ J UROL, 2021, 47 (04): : 705 - 729
  • [42] Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging
    Cardinale, Jens
    Schaefer, Martin
    Benesova, Martina
    Bauder-Wuest, Ulrike
    Leotta, Karin
    Eder, Matthias
    Neels, Oliver C.
    Haberkorn, Uwe
    Giesel, Frederik L.
    Kopka, Klaus
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (03) : 425 - 431
  • [43] Detection Rate of 18F-labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Meta-analysis
    Treglia, G.
    Annunziata, S.
    Pizzuto, D. A.
    Ceriani, L.
    Giovanella, L.
    Prior, J. O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S606 - S606
  • [44] Prostate-Specific Membrane Antigen-Avid Neurofibroma Mimicking Cutaneous Metastasis in Metastatic Castration-Resistant Prostate Cancer on 18F-PSMA-1007 PET/CT
    Aggarwal, Piyush
    Ambalavanan, Nivetha
    Sood, Ashwani
    Gupta, Kirti
    Dahiya, Divya
    Mittal, Bhagwant Rai
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : e286 - e287
  • [45] Prostate-Specific Membrane Antigen PET/CT Detection of Prostate Cancer Metastasis to Thyroid and Cricoid Cartilages
    Eichhorn, Joshua
    Nelson, Nadia
    Raichandani, Surbhi
    Sesler, Aaron
    Manzil, Fathima Fijula Palot
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (05) : 481 - 483
  • [46] Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer
    Prive, Bastiaan M.
    Israel, Bas
    Janssen, Marcel J. R.
    van der Leest, Marloes M. G.
    de Rooij, Maarten
    van Ipenburg, Jolique A.
    Jonker, Marianne
    Peters, Steffie M. B.
    de Groot, Michel
    Zamecnik, Patrik
    Hoepping, Alexander
    Bomers, Joyce G.
    Gotthardt, Martin
    Sedelaar, J. P. Michiel
    Barentsz, Jelle O.
    van Oort, Inge M.
    Nagarajah, James
    RADIOLOGY, 2024, 311 (02)
  • [47] Initial evaluation of PET/CT with 18F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients
    Saga, Tsuneo
    Nakamoto, Yuji
    Ishimori, Takayoshi
    Inoue, Takahiro
    Shimizu, Yoichi
    Kimura, Hiroyuki
    Akamatsu, Shusuke
    Goto, Takayuki
    Watanabe, Hiroyuki
    Kitaguchi, Kosuke
    Watanabe, Masao
    Ono, Masahiro
    Saji, Hideo
    Ogawa, Osamu
    Togashi, Kaori
    CANCER SCIENCE, 2019, 110 (02): : 742 - 750
  • [48] Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
    Awenat, Salam
    Piccardo, Arnoldo
    Carvoeiras, Patricia
    Signore, Giovanni
    Giovanella, Luca
    Prior, John O.
    Treglia, Giorgio
    DIAGNOSTICS, 2021, 11 (03)
  • [49] Detection support of lesions in patients with prostate cancer using 18F-PSMA 1007 PET/CT
    Tsuchiya, Naoki
    Kimura, Koichiro
    Tateishi, Ukihide
    Watabe, Tadashi
    Hatano, Koji
    Uemura, Motohide
    Nonomura, Norio
    Shimizu, Akinobu
    INTERNATIONAL JOURNAL OF COMPUTER ASSISTED RADIOLOGY AND SURGERY, 2024, 19 (04) : 613 - 623
  • [50] Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis
    Guo, Yu
    Wang, Ling
    Hu, Junjie
    Feng, Dehong
    Xu, Lijuan
    PLOS ONE, 2018, 13 (09):